Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H19ClFN5O3 |
| Molecular Weight | 419.837 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COCC1=NN=C(N2CC(C2)OC3=C(Cl)C=C(F)C=C3)N1C4=CN=C(OC)C=C4
InChI
InChIKey=HNIFCPBQMKPRCX-UHFFFAOYSA-N
InChI=1S/C19H19ClFN5O3/c1-27-11-17-23-24-19(26(17)13-4-6-18(28-2)22-8-13)25-9-14(10-25)29-16-5-3-12(21)7-15(16)20/h3-8,14H,9-11H2,1-2H3
PF-3274167 (Cligosiban) is a potent, selective, brain penetrant oxytocin receptor antagonist. Cligosiban interrupts the expulsion phase of ejaculation by reducing the normal bulbospongiosum burst pattern and reducing the expulsions that accompany bursts. Cligosiban represents a promising compound to test the clinical hypothesis that antagonism of central oxytocin receptors may be of therapeutic benefit in the treatment of premature ejaculation. [11C]PF-3274167 is not a suitable tracer for imaging of OTR in rat brain, probably because of a too low affinity for this receptor in addition to a poor brain penetration. PF-3274167 had been in phase I clinical trial for the treatment of sexual function disorders and urinary incontinence. However, this research has been discontinued.
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [(11)C]PF-3274167 as a PET radiotracer of oxytocin receptors: Radiosynthesis and evaluation in rat brain. | 2017 Dec |
|
| Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects. | 2019 Feb |
|
| Pharmacokinetics of cligosiban in dog plasma after oral administration by liquid chromatography electrospray ionization tandem mass spectrometry. | 2019 Oct |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
10778
Created by
admin on Sat Dec 16 10:03:29 GMT 2023 , Edited by admin on Sat Dec 16 10:03:29 GMT 2023
|
PRIMARY | |||
|
C171859
Created by
admin on Sat Dec 16 10:03:29 GMT 2023 , Edited by admin on Sat Dec 16 10:03:29 GMT 2023
|
PRIMARY | |||
|
D361S17AIF
Created by
admin on Sat Dec 16 10:03:29 GMT 2023 , Edited by admin on Sat Dec 16 10:03:29 GMT 2023
|
PRIMARY | |||
|
900510-03-4
Created by
admin on Sat Dec 16 10:03:29 GMT 2023 , Edited by admin on Sat Dec 16 10:03:29 GMT 2023
|
PRIMARY | |||
|
100000181102
Created by
admin on Sat Dec 16 10:03:29 GMT 2023 , Edited by admin on Sat Dec 16 10:03:29 GMT 2023
|
PRIMARY | |||
|
11683187
Created by
admin on Sat Dec 16 10:03:29 GMT 2023 , Edited by admin on Sat Dec 16 10:03:29 GMT 2023
|
PRIMARY | |||
|
PF-3274167
Created by
admin on Sat Dec 16 10:03:29 GMT 2023 , Edited by admin on Sat Dec 16 10:03:29 GMT 2023
|
PRIMARY | Biological Activity of PF-3274167: PF-3274167 is a high-affinity nonpeptide oxytocin receptor (OTR) antagonist, with Ki of 9.5 nM., IC50 value: 9.5 nM (1), Target: oxytocin receptor (OTR) | ||
|
IX-01
Created by
admin on Sat Dec 16 10:03:29 GMT 2023 , Edited by admin on Sat Dec 16 10:03:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
